Avid Bioservices Inc expected to post a loss of 6 cents a share - Earnings Preview

Avid Bioservices

05/12/2023 21:12

* Avid Bioservices Inc  CDMO.OQ   CDMO.O  is expected
to show a
fall in quarterly revenue when it reports  results  for the
period ending July 31 2023
    * The Tustin California-based  company is expected to report
a
4.4% decrease in revenue to $33.212 million from $34.76 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Avid Bioservices Inc is
for a
loss of 6 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avid
Bioservices
Inc is $18.50​, above​ its last closing price of $5.43. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jul. 31 2023  -0.03       -0.03      -0.03     Met     -9.1
 Apr. 30 2023  0.00        0.00       0.00      Met     
 Jan. 31 2023  -0.04       -0.03      0.01      Beat    128.6​
 Oct. 31 2022  0.00        0.00       -0.02     Missed  -300
 ​​Jul.        0.04        0.04       0.02      Missed  -45.5
 31 2022                                                
 Apr. 30 2022  0.01        0.01       0.01      Met     0​
 Jan. 31 2022  0.05        0.04       0.04      Met     0
 Oct. 31 2021  0.03        0.03       0.06      Beat    140
 This summary was machine generated December 5 at 21:11 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)